Pharmaceutical dosage system

A pharmaceutical dosage system comprising:

• an inner wallet that includes multiday blister pack having a plurality of blisters that at least partially define a corresponding plurality of cavities, and an inner panel that carries the blister pack, wherein the blisters extend through respective openings of the inner panel;
• and
• a plurality of pharmaceutical dosage forms disposed in respective cavities of the plurality of cavities, such that each cavity of the plurality of cavities contains only a single one of the plurality of pharmaceutical dosage forms, wherein the cavities are accessible so as to consume the pharmaceutical dosage forms on respective unique days over a multi-day period, and all active ingredients of each of the pharmaceutical dosage forms are substantially identical to each other,
• wherein the pharmaceutical dosage forms are arranged along the inner wallet sequentially in the order in which they are to be consumed,
• wherein each of the pharmaceutical dosage forms includes indicia that visually distinguish each of the pharmaceutical dosage forms from one or more others of the single pharmaceutical dosage forms,
• wherein the inner wallet contains earmarking information that sets forth a dosing schedule during which of the pharmaceutical dosage forms are to be consumed over the multi day period, and
• wherein the pharmaceutical dosage forms comprise:
• two of a first pharmaceutical dosage form earmarked by the earmarking information to be consumed on respective first and second days of the multi-day period, wherein the first pharmaceutical dosage forms contain approximately 2 mg of active ingredient;
• two of a second pharmaceutical dosage form earmarked by the earmarking information to be consumed on respective third and fourth days of the multi-day period, wherein the second pharmaceutical dosage forms contain approximately 3 mg of active ingredient;
• two of a third pharmaceutical dosage form earmarked by the earmarking information to be consumed on respective fifth and sixth days of the multi-day period, wherein the third pharmaceutical dosage form contains approximately 4 mg of active ingredient;
• a fourth pharmaceutical dosage form earmarked by the earmarking information to be consumed on a seventh day of the multi-day period, wherein the fourth pharmaceutical dosage form contains approximately 5 mg of active ingredient;
• a fifth pharmaceutical dosage form earmarked by the earmarking information to be consumed on an eighth day of the multi-day period, wherein the fifth pharmaceutical dosage form contains approximately 6 mg of active ingredient;
• a sixth pharmaceutical dosage form earmarked by the earmarking information to be consumed on a ninth day of the multi-day period, wherein the sixth pharmaceutical dosage form contains approximately 7 mg of active ingredient;
• a seventh pharmaceutical dosage form earmarked by the earmarking information to be consumed on a tenth day of the multi-day period, wherein the seventh pharmaceutical dosage form contains approximately 8 mg of active ingredient;
• an eighth pharmaceutical dosage form earmarked by the earmarking information to be consumed on an eleventh day of the multi-day period, wherein the eighth pharmaceutical dosage form contains approximately 9 mg of active ingredient;
• and
• three of a ninth pharmaceutical dosage form earmarked by the earmarking information to be consumed on respective twelfth, thirteenth, and fourteenth days of the multi-day period, wherein the ninth pharmaceutical dosage form contains approximately 10 mg of active ingredient.